论文部分内容阅读
1957年Sensi等人发现利福霉素,1963年Prelog等人阐明其分子结构以来,至今已发展成一族中等规模的抗生素。 利福霉素族中某些成员对革蓝氏阳性菌的强烈毒杀作用,尤其是对结核杆菌的杀灭过程和特异的生理作用,引起了临床医生的关注。世界上已有几种利福霉素被广泛用于治疗疾病,并取得显著疗效。 但是,人们在使用利福霉素过程中很快发现了耐药菌株,进一步研究利福霉素衍生物时又发现随衍生物上取代基的不同,其抗菌谱和生理作用均有相应改变。提示药物、细菌和人体三者间存在相关因素,因此人们必须探求新一代的利福霉素,以解决临床上新的要求。
In 1957, Sensi et al. Found that rifamycin and Prelog et al. In 1963 elucidated their molecular structure and so far they have developed into a family of medium-sized antibiotics. Some members of the rifamycins strongly inactivate gram-positive bacteria, especially the killing process and specific physiological effects on M. tuberculosis, which have aroused clinicians’ attention. Several types of rifamycins have been widely used in the world to treat diseases and have achieved remarkable results. However, people quickly found rifamycin resistant strains, further study of rifamycin derivatives also found that with the different derivatives on the derivative, the antibacterial spectrum and physiological effects are changed accordingly. Tip drugs, bacteria and human factors exist between the three, so people have to explore a new generation of rifamycin, to solve the new clinical requirements.